



CanVECTOR Member Oral & Poster Presentations

[ISTH 2023 – Montreal, CA](#)

June 24th – 28th

[Sat 24th](#) | [Sun 25th](#) | [Mon 26th](#) | [Tue 27th](#) | [Wed 28th](#)

(Scroll using links or bookmarks)

Saturday, June 24th, 2023

| Day/ Time/ Location/ Theme | Title | Authors |
|---|--|---|
| Time: 13:00 – 13:15 ET Location: Rm 520 Abstract Number: OC 04.1 Theme: Hemophilia and Rare Bleeding Disorders | Exploring the hemostatic properties of extravascular factor IX in a hemophilia B mouse model | Chu B, Zaheer W, Tieu P, Madarati H, Kretz C, Gross P, Chan A, Matino D |

| | | |
|--|---|---|
| Time: 13:15 – 13:30 Location: Rm 511 Abstract Number: OC 05.2 Theme: COVID | Impact of heparin on disease state transition in hospitalized, non-critically ill patients with COVID-19; secondary analysis of an international multi-platform RCT | Tays Q, Carrier M, Castellucci L |
| Time: 13:30 – 13:45 Location: Rm 516 Abstract Number: OC 01.3 Theme: Venous Thromboembolism | Systemic and catheter-directed thrombolysis in high and intermediate-high risk pulmonary embolism: a systematic review with meta-analysis | Mai V, Carrier M, Le Gal G, Castellucci L |
| Time: 14:00 – 14:15 Location: Rm 516 Abstract Number: OC 01.5 Theme: Venous Thromboembolism | Anticoagulation Post-Pulmonary Endarterectomy: A retrospective cohort study | Raslan I, De Perrot M, Yeo E, Abdulrehman J |
| Time: 15:00 – 15:10 Location: Rm 516 Abstract Number: SSC 04.4 | SSC Project: Systematic Review CART associated bleeding | Wang T-F |
| Sunday June 25th, 2023 | | |
| Day/ Time/ Location/ Theme | Title | Authors |
| Time: 08:43 – 09:03 Location: Rm 710A Abstract Number: SOA 07.3 | Saving Women’s Lives Globally With Tranexamic Acid: Barriers to Access and Myths Surrounding Its Use | Sholzberg M |

| | | |
|---|--|--|
| <p>Time: 10:45 – 11:00 Location: Rm 516</p> <p>Abstract Number: LB 01.1 Theme: Hemophilia and Rare bleeding disorders</p> | <p>Development and validation of a clinical prediction model for the diagnostic management of acute pulmonary embolism: an individual participant data meta-analysis</p> | <p>Van Es N, Takada T, Kraajipoel N, Klok E, Stals M, Buller H, Courtney M, Freund Y, Le Gal G, Ghanima W, Huisman M, Kline J, Moons C, Righini M, Parpia S, Roy P, Wells P, de Wit K, van Smeden M, Geersing G</p> |
| <p>Time: 11:00- 11:15 Location: Rm 516</p> <p>Abstract Number: OC 11.2 Theme: Venous Thromboembolism</p> | <p>Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: post-hoc analysis of the PEP trial</p> | <p>Mai V, Rambaud G, Motreff C, Sanchez O, Roy P, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Nonent M, Tromeur C, Salaun P, Mismetti P, Girard P, Lacut K, Meyer G, Leroyer C, Le Gal G, Bertolletti L, Couturaud F</p> |
| <p>Time: 11:00 – 11:15 Location: Rm 524</p> <p>Abstract Number: OC 17.2 Theme: Venous Thromboembolism</p> | <p>New insights on the genetics of venous thromboembolism recurrence from a GWAS analysis of 6,504 patients including 1,797 recurrent events</p> | <p>Munsch G, Brody J, Vlieg H, Thibord F, Gagnon F, Gourhant L, Goumidi L, Germain M, Boland A, Deleuze J, Jacquemin-Gadda H, Smith N, Rosendaal F, Johnson A, Rodger M, Courturaud F, Morange P, Tregouet D</p> |
| <p>Time: 11:15 – 11:30 Location: Rm 516</p> <p>Abstract Number: OC 11.3 Theme: Venous Thromboembolism</p> | <p>Association between body mass index and pulmonary embolism and performance of the age-adjusted D-dimer strategy in obese patients with suspected pulmonary embolism: a prospective management study</p> | <p>Gaugler J, Righini M, Robert-Ebadi H, Sanchez O, Roy P, Verschuren F, Miranda S, Delluc A, Le Gal G, Tritschler T</p> |
| <p>Time: 11:15 – 11:30 Location: Rm 517</p> <p>Abstract Number: LB 01.3 Theme: Fibrinolysis & Proteolysis</p> | <p>Factor XIII 24-Hour Trajectory Analysis in Severely Injured Patients: Post-Hoc Analysis of the Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Study</p> | <p>Gomez Builes J, Sholzberg M, Nisenbaum R, Karkouti K, Barahi S, Castello M, Bai J, Daza J, Callum J, Baker A</p> |

| | | |
|---|---|--|
| <p>Time: 11:45 – 12:00 Location: Rm 516</p> <p>Abstract Number: OC 11.5 Theme: Venous Thromboembolism</p> | <p>Diagnostic strategies in patients on anticoagulation presenting with a suspicion of recurrent venous thromboembolism</p> | <p>Mai V, Martens E, Righini M, Schulman S, Thiruganasambandamoorthy V, Kahn S, Bates V, Pecarskie A, Kovacs M, Visser S, Shivakumar S, Tan M, Rodger M, Scarvelis D, Delluc A, Girard P, Huisman M, Wells P, Klok E, Le Gal G</p> |
| <p>Time: 14:45 – 15:00 Location: Rm 520</p> <p>Abstract Number: OC 24.1 Theme: Hemophilia & Rare Bleeding Disorders</p> | <p>Effect of the type of F9 mutation on the pharmacokinetic profile of patients with hemophilia B treated with extended half-life FIX concentrates.</p> | <p>Matino D, Chelle P, Jackson S, Teitel J, Castaman G, Keepanasseril A, Iserman E, Lillicrap D, Chan A, Iorio A</p> |
| <p>Time: 15:15 – 15:30 Location: Rm 516</p> <p>Abstract Number: OC 21.3 Theme: Venous Thromboembolism</p> | <p>Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment – a nationwide register study</p> | <p>Sandblad K, Schulman S, Rosengren A, Sorbo J, Philipson J, Hansson P</p> |
| <p>Time: 15:15 – 15:30 Location: Rm 511</p> <p>Abstract Number: OC 25.3 Theme: Women's Health</p> | <p>A multicentre cohort study evaluating pregnancy loss in patients with von Willebrand disease and unspecified bleeding disorders</p> | <p>Skeith L, James P, Kouides P, Uminski K, Duffett L, Jackson S, Sholzberg M, Ragni M, Cuker A, O'Beirne M, Rubinstein S, Hews-Girard J, Rydz N, Goodyear D, Baxter J, James A, Garcia D, Vesely S, Poon M</p> |
| <p>Time: 15:30 – 15:45 Location: Rm 520</p> <p>Abstract Number: OC 24.4 Theme: Hemophilia & Rare Bleeding Disorders</p> | <p>Effect of F8 mutations and Von Willebrand factor on pharmacokinetics of FVIII concentrates in severe hemophilia A</p> | <p>Germini F, Housni Z, Chan A, Decker K, Iorio A, Matino D</p> |

| | | |
|---|---|--|
| Time: 15:30 – 15:45 Location: Rm 710 A Abstract Number: OC 29.4 Theme: COVID | Impact of symptom duration on clinical outcomes in hospitalized, non-critically ill patients with COVID-19; secondary analysis of an international multi-platform RCT | Tays Q, Teng W, Houston B, Balshaw R, Lawler P, Lothar S, Garland A, Mendelson A, Rimmer E, Houston D, Neal M, Faroukh M, Carrier M, Goligher E, Castellucci L, Falk J, Ariano R, Heath A, Zarychanski R |
| Time: 15:45 – 16:00 Location: Rm 515 Abstract Number: OC 22.5 Theme: COVID | Effect of angiostatin and its neutralization on cellular infection by SARS-CoV and SARS-CoV-2 | Franczak A, Joyce M, Saito M, Tyrrell L, Jurasz P |
| Time: 16:35 – 16:55 Location: Rm 710 B Abstract Number: SSC 11.2 | Current Projects Update: ISTH Guidelines for Anticoagulation in COVID19-1 | Schulman S |
| Time: 17:50 – 18:02 Location: Rm 517 Abstract Number: SSC 07.9 | Registry on augmented antithrombotic treatment regimens for patients with arterial thrombotic APS | Schulman S |
| <u>Poster Abstracts - Sunday June 25th, 2023</u> | | |
| Time: 18:30 – 19:30 Location: Exhibition | | |
| Abstract Number: PB0315 Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies | Characterizing Protease-Resistant ADAMTS13 Mutants | DeYoung V, Madarati H, Teney C, Kretz C |

| | | |
|---|--|--|
| Abstract Number: PB0327 Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies | Modulating ADAMTS13 Activity Using Organic Solvents | Andrisani P, Kretz C, Singh K |
| Abstract Number: PB0338 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies | The ideal acetylsalicylic acid (ASA) dose to combine with P2Y12 inhibitors: a volunteer study | Gross P, Ballagh R, Killingbeck B, Ni R |
| Abstract Number: PB0052 Theme: COVID | Heparin type & clinical outcomes in hospitalized, non-critically ill patients with COVID-19: secondary analysis of an international multi-platform RCT | Tays Q, Houston B, Teng W, Balshaw R, Lawler P, Lothar S, Garland A, Faroukh M, Carrier M, Goligher E, Castellucci L, Ariano R, Falk J, Heath A, Zarychanski R |
| Abstract Number: PB0424 Theme: Platelets and Megakaryocytes | The critical role of filamin A in the platelet shape change reaction | Hong F, De Silva E, Kim H |
| Abstract Number: PB0449 Theme: Venous Thromboembolism | Impact of self-reported race on Villalta Scale scores and correlation with venous disease specific quality of life: an exploratory analysis of the ATTRACT Trial | Gu C, Vedantham S, Kaufman J, Kahn S |
| Abstract Number: PB0450 Theme: Venous Thromboembolism | Does Iliac Vein Stenting Reduce the Severity of Post-Thrombotic Syndrome? Progress on an Ongoing Multicenter Randomized Controlled Trial | Vedantham S, Parpia S, Kahn S |
| Abstract Number: PB0459 Theme: Venous Thromboembolism | The Impact of Gastrointestinal Surgeries on peak plasma anti-Xa Direct Oral Anticoagulant levels | Huoy M, Selby R, Sutradhar S, Abdulrehman J |
| Abstract Number: PB0474 Theme: Venous Thromboembolism | Anticoagulant management and outcomes in non-traumatic intracranial hemorrhage complicated by venous thromboembolism | Schulman S, Gorman J, Candeloro M |

| | | |
|--|---|--|
| Abstract Number: PB0475 Theme: Venous Thromboembolism | Empowering patient ambassadors to champion research outcomes that are a priority for people who have lived experience with venous thromboembolism (VTE) | West C, Langlois N, Lowthian T, Dubois S, Duffett L |
| Abstract Number: PB0477 Theme: Venous Thromboembolism | Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension | Benzidia I, Robitaille C, Abaulsaud A, McDonald L, Lesenko L, Morin J, Langleben D, Kahn S, Hirsch A |
| Abstract Number: PB0479 Theme: Venous Thromboembolism | The ABC-bleeding score for prediction of on-treatment clinically relevant bleeding in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study | Guman N, Becking A, Mulder F, Carrier M, Ageno W, Klok E |
| Abstract Number: PB0486 Theme: Venous Thromboembolism | Effect of Age on Risk for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis | Xu Y, Carrier M, Le Gal G, Marcucci M, Rodger M, Khan F |
| Abstract Number: PB0493 Theme: Venous Thromboembolism | Top 10 VTE Research Priorities of Patients and Clinicians: Clot Top 10 Priorities Results | Duffett L, Christopher D, Delluc A, de Wit K, Dubois S, Linkins L, Morneault D, Ostrowski M, West C |
| Monday, June 26th, 2023 | | |
| Day/ Time/ Location/ Theme | Title | Authors |
| Time: 07:00 – 07:45 Location: Delafond Room at Intercontinental Mtrl Abstract Number: MC 11.1 Theme: Venous Thromboembolism | A Primer on Starting a Clinical Thrombosis Program | Skeith L |

| | | |
|---|--|---|
| <p>Time: 07:00 – 07:45 Location: Fraser Room at Intercontinental Mtrl Abstract Number: MC 20.1 Theme: Fibrinolysis & Proteolysis</p> | <p>The Role of Tranexamic Acid in Prevention and Management of Bleeding</p> | <p>Sholzberg M</p> |
| <p>Time: 10:45 – 11:00 Location: Rm 516 Abstract Number: OC 31.1 Theme: Coagulation and Natural Anticoagulants</p> | <p>Management and Outcomes of Anticoagulated Patients in Urgent Surgery: The PAUSE-ER Study</p> | <p>Siegal D, Arnaoutoglou E, Blostein M, Castellucci L, Eikelboom J, Gandhi R, Gross P, Kaatz S, Le Gal G, Schulman S, Shah V, Stamoulis K, Tafur A, Vogt K, Nixon J, St John M, Karunakaran M, LEvoy – Jones B, Douketis J</p> |
| <p>Time: 11:00 – 11:10 Location: Rm 510 Abstract Number: OC 36.2 Theme: Venous Thromboembolism</p> | <p>Machine-learning based risk prediction of cancer associated thrombosis: internal, external, and pre-clinical validation studies</p> | <p>Patell R, Karagkouni D, Brake M, Falanga A, Marchetti M, Russo L, Mantha S, Carrier M, Wells P, Neuberg D, Ren S, Flaumenhaft R, Iachos I, Schulman S, Zwicker J</p> |
| <p>Time: 11:00 – 11:15 Location: Rm 710 A Abstract Number: OC 32.2 Theme: Venous Thromboembolism</p> | <p>Risk of Venous Thromboembolism and Major Bleeding in Patients with Acute Medical Illness Receiving Thromboprophylaxis with Enoxaparin</p> | <p>Le Gal G, Agnelli G, Darius H, Kahn S, Owaidah T, Thereza A, Sanchez O, Zhai Z, Khan I, Djoudi Y, Ponomareva E, Cohen A</p> |
| <p>Time: 11:15 – 11:30 Location: Rm 516 Abstract Number: OC 31.3 Theme: Coagulation and Natural Anticoagulants</p> | <p>Phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of VMX-C001 in healthy subjects</p> | <p>Short G, Verhoef D, Gomes T, Spronk H, Ohrstrom J, Persson B, Weitz J, Reitsma P</p> |

| | | |
|--|--|--|
| <p>Time: 11:30 – 11:45 Location: Rm 518</p> <p>Abstract Number: OC 38.4 Theme: Pediatrics</p> | <p>Transient Antiphospholipid Antibodies, Antiphospholipid Syndrome and Clinical Outcomes in Patients <21 Years Old with Provoked Venous Thromboembolism: Analysis from the Kids-DOTT Multinational Trial</p> | <p>Betensky M, Mosha M, Tarango C, Anupam V, Bhat R, Kucine N, Nakano T, Woods G, Nakar C, Amankwah E, Brandao L, Schulman S, Goldenberg N</p> |
| <p>Time: 14:45 – 15:00 Location: Rm 510</p> <p>Abstract Number: OC 46.1 Theme: Venous Thromboembolism</p> | <p>Absolute quantitative proteomics for occult cancer screening in patient with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study</p> | <p>Guman N, Kraaijpoel N, Mulder F, Carrier M, Jara-Palomares L, Di Nisio M, Ageno W, Beyer-Westendorf J</p> |
| <p>Time: 15:30 – 15:45 Location: Rm 710 A</p> <p>Abstract Number: OC 42.4 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Usefulness of 1E12, a monoclonal anti-Platelet Factor 4 antibody to improve diagnosis of vaccine-induced immune thrombotic thrombocytopenia</p> | <p>Rollin J, Vayne C, Clare R, Atsouawe M, Cordonnier C, Lemoine S, Godon A, Susen S, Nazy I, Gruel Y, Puoplard C</p> |
| <p>Time: 15:45 – 16:00 Location: Rm 517</p> <p>Abstract Number: OC 40.5 Theme: Venous Thromboembolism</p> | <p>Risk of All-Cause Mortality following Anticoagulant Cessation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis</p> | <p>Xu Y, Tritschler T, Carrier M, Le Gal G, Marcucci M, Couturaud F, Prandoni P, Palareti G, Kyrle P, Eichinger S, Becattini C, Agnello G, Brighton T, Bauersachs R, Gebel M, Bradbury C, Andreozzi G, Fergusson D, Rodger M, Khan F</p> |
| <p>Time: 17:45 – 18:00 Location: Rm 511</p> <p>Abstract Number: SSC 19.7</p> | <p>The balance of hemostasis and fibrinolysis-clinical perspectives in pregnancy</p> | <p>Othman M</p> |

| | | |
|--|---|---|
| Time: 18:17 – 18:27 Location: Rm 517 Abstract Number: SSC 16.15 | Challenges in management of women with type 2B VWD during pregnancy - A need for international guidance | Othman M |
| <u>Poster Abstracts – Monday, June 26th, 2023</u> | | |
| Time: 18:30 – 19:30 Location: Exhibition | | |
| Abstract Number: PB 0604 Theme: COVID | The VWF-ADAMTS13 axis as biomarkers of disease progression in severe COVID-19 | Bowman M, Grabell J, Yeh C, Gross P, Fox-Robichaud A, Kim P, Lillicrap D, James P |
| Abstract Number: PB 0734 Theme: Hemostatic Systems in Cancer, Inflammation and Immunity | Platelet Procoagulant Potential Increases Following Thromboprophylaxis Completion in Patients with Primary Breast Cancer and Surgically Treated Metastatic Bone Disease | Yamaura L, Young D, Salazar-Arcila C, Monument M, Skeith L, Dufour A, Schneider P, O.Agbani E |
| Abstract Number: PB 0777 Theme: Immunothrombosis | The Risk of Thrombosis in Patients with Acute Lymphoblastic Leukemia may be Explained by the Impact of Peripheral Blasts on Endothelial Cells: An In-vitro study | Tieu P, Stevic I, Athale U, Kretz C, Matino D, Chan A |
| Abstract Number: PB 0808 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies | Localized Endothelial Colony-Forming Cell-derived von Willebrand Factor (VWF) influences In Vivo Angiogenesis in VWF-deficient Mice | Ocran E, Burnett E, Bowman M, Rawley O, Maurice D, Lillicrap D, James P |
| Abstract Number: PB 0809 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies | Transcriptional coactivators YAP and TAZ contribute differently to the transcriptional regulation of VWF in venous and arterial endothelial cells | O'Donnell M, Tijet N, Notely C, Lillicrap D |

| | | |
|---|--|--|
| <p>Abstract Number: PB 0815 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Involvement of the nuclear protein, TC2N, in regulating VWF levels in endothelial cells</p> | <p>Bowman M, James P, Lillicrap D</p> |
| <p>Abstract Number: PB 0846 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Membrane Procoagulation and N-Terminomics/TAILS Profiling in Montreal Platelet Syndrome Kindred with VWF p.V1316M mutation</p> | <p>Agbani E, Young D, Chen S, Smith S, Lee A, Poole A, Dufour A, Poon M</p> |
| <p>Abstract Number: PB 0899 Theme: Platelets and Megakaryocytes</p> | <p>Connexin 45 is co-localized with Coxsackievirus-adenovirus receptor forming contact membrane within platelet aggregates and filopodia</p> | <p>Rimskaya E, Buraychklovskaya L, Mironova N, Chumachenko P, Othman M</p> |
| <p>Abstract Number: PB 0947 Theme: Venous Thromboembolism</p> | <p>The Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma: A Systematic Review</p> | <p>Suleman A, Wine R, Carrier M, Hicks L</p> |
| <p>Abstract Number: PB 0965 Theme: Venous Thromboembolism</p> | <p>Delphi Survey of Canadian Physicians to Determine Optimal Anticoagulant Treatment Approaches for Patients with Cancer and Splanchnic Venous Thrombosis</p> | <p>Zahrai A, Delluc A, Carrier M</p> |
| <p>Abstract Number: PB 0974 Theme: Venous Thromboembolism</p> | <p>Safety of direct oral anticoagulant (DOAC) in adult patients with venous thromboembolism or non-valvular atrial fibrillation in the context of urogenital and gynecological cancer: systematic review</p> | <p>Altourah L, Ikesaka R</p> |
| <p>Abstract Number: PB 0983 Theme: Venous Thromboembolism</p> | <p>Assessing Hypercoagulability and VTE Risk using Thromboelastography and Khorana Score in Women Receiving Chemotherapy for Breast and Gynecological</p> | <p>Othman M, Fainchtein K, Assar M, Jin Suh Y, Karizhenskaia M, Agrawal A, Mates M, Tera Y</p> |

| | | |
|---|--|---|
| Abstract Number: PB 0993 Theme: Venous Thromboembolism | Thromboelastometry (ROTEM) in detection of hypercoagulability in patients referred for thrombophilia screening | Assar M, Nilius H, Kearn N, Hopman W, Nagler M, Othman M |
| Abstract Number: PB 1006 Theme: Venous Thromboembolism | Accuracy and interrater agreement of death event adjudications by physician trainees: Validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort | Marx C, Schenker C, Xu Y, Salvatore S, Kahn S, Garcia D, Delluc A, Kraaijpoel N, Langlois N, Girard P, Le Gal G, Tritschler T |
| Abstract Number: PB 1007 Theme: Venous Thromboembolism | Diagnostic yield of imaging for pulmonary embolism by presenting complaint in the emergency department: an observational study. | Germini F, Al-haimus F, Hu Y, Klyn J, Ikesaka R, Chan N, Clayton N, Ibrahim Q, de Wit K |
| Abstract Number: PB 1008 Theme: Venous Thromboembolism | The diagnostic performance of the YEARS and PEGeD algorithm in patients with prior venous thrombosis suspected of pulmonary embolism | Martens E, Mai V, Bates V, Delluc A, Girard P, Huisman M, Kahn S, Kovacs M, Pecarskie A, Rodger M, Scarvelis D, Schulman S, Shivakumar S, Visser S, Wells P, Le Gal G, Klok E |
| Tuesday, June 27th, 2023 | | |
| Day/ Time/ Location/ Theme | Title | Authors |
| Time: 07:00 – 07:45 Location: Ravel Room at Intercontinental Mtrl Abstract Number: MC 24.1 Theme: Venous Thromboembolism | Going Beyond the Patient as a Research Participant: Engaging and Partnering With Patients in Research Planning | Duffett L |
| Time: 08:25 – 08:50 Location: Rm 710 A Abstract Number: SOA 20.2 Theme: Women’s Health | Postpartum VTE Prevention: Lessons from the Pilot PARTUM Trial | Skeith L |

| | | |
|---|---|--|
| <p>Time: 10:45 – 11:00 Location: Rm 511</p> <p>Abstract Number: OC 54.1 Theme: Venous Thromboembolism</p> | <p>Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of OSCAR Programme Findings</p> | <p>Coleman C, Snow-Caroti K, Rivera M, Becattini C, Carrier M</p> |
| <p>Time: 11:00 – 11:15 Location: Rm 517 Abstract Number: LB 02.2 Theme: Venous Thromboembolism</p> | <p>Prevention of Symptomatic Venous Thromboembolism with Low-Molecular-Weight Heparin in Hospitalized Older Adult Medical Patients: a Randomized Placebo-Controlled Trial</p> | <p>Mottier D, Girard P, Couturaud F, Le Moigne E, Paleiron N, Le Gal G</p> |
| <p>Time: 11:30 – 11:45 Location: Rm 511</p> <p>Abstract Number: OC 54.4 Theme: Venous Thromboembolism</p> | <p>Multinational Cohort Analysis of Intracranial Hemorrhage Outcomes in Patients with Brain Tumors Receiving Anticoagulation (ABC Study)</p> | <p>Leader A, Hamulyak E, Wang T-F, Carrier M</p> |
| <p>Time: 11:45 – 12:00 Location: Rm 517</p> <p>Abstract Number: LB 02.5 Theme: Immunothrombosis</p> | <p>Distinct Antibody Groups in Patients With Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) And Their Clinical Implications</p> | <p>Nazy I, Huynh A, Arnold D</p> |
| <p>Time: 15:30 – 15:45 Location: Rm 520</p> <p>Abstract Number: OC 63.4 Theme: Venous Thromboembolism</p> | <p>Prevalence of pulmonary embolism in patients with chronic obstructive pulmonary disease exacerbation in North America – a single center experience</p> | <p>Mai V, Pradier M, Mulpuru S, Thiruganasambandamoorthy V, Code C, Le Gal G</p> |
| <p>Time: 16:30 – 16:40 Location: Rm 520</p> <p>Abstract Number: SSC 24.1</p> | <p>Session Welcome - Models of Thrombosis & Hemostasis</p> | <p>Gross P</p> |

| | | |
|--|---|---|
| Theme: SSC Session - Models of Thrombosis & Hemostasis | | |
| Time: 17:31 – 17:41 Location: Rm 710 A Abstract Number: SSC 20.7 | Re-evaluating the ISTH definitions of major bleeding and clinically relevant non-major bleeding | Castellucci L |
| <p>Poster Abstracts – Tuesday, June 27th, 2023</p> <p>Time: 18:30 – 19:30 Location: Exhibition</p> | | |
| Abstract Number: PB 1033 Theme: Coagulation and Natural Anticoagulants | Delphi consensus recommendations for neuraxial anesthesia in adults with platelet disorders and coagulation defects | Peterson W, Martin R, Arnold D, Carvalho B, Cuker A, Provan D, Rydz N, Shore E, Kuter D, Kouides P, Lavin M, James P, Engen D, Sholzberg M |
| Abstract Number: PB 1200 Theme: Fibrinolysis and Proteolysis | Evaluation of the association of factor XIII at hospital arrival and outcomes in a cohort of severely injured patients | Gomez Builes J, Baker A, Callum J, Barahi S, Bai J, Karkouti K, Nisenbaum R, Sholzberg M |
| Abstract Number: PB 1299 Theme: Hemophilia and Rare Bleeding Disorders | Obstetrical decision-making in moderate or severe hemophilia A and B: a qualitative study exploring parents' experiences, preferences and needs | Lane S, Carter N, Aber E, Crane J, Emberley J, Heddle N, Klaassen R, Sholzberg M, Chan A |
| Abstract Number: PB 1312 Theme: Hemophilia and Rare Bleeding Disorders | "The doctor says so" – Patient Values and Preferences Regarding Resumption of Oral Anticoagulation After Gastrointestinal Bleeding | Awada N, Chien K, Little D, Carrier M, Deal K, Dionne J, Douketis J, Forbes N, Holbrook A, Ostrowski M, Robertson T, Stacey D, West C, Xenodemetropoulos T, Xie F, Siegal D |

| | | |
|---|---|--|
| <p>Abstract Number: PB 1334 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases</p> | <p>Sholzberg M, Gwathmey K, Broome C, Goebeler M, Murai H, Bata-Csorgo Z, Newland A, Ulrichs P, Kerstens R, Guptill J, Agha S, Jiang M, Howard J</p> |
| <p>Abstract Number: PB 1347 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Evaluating local practice patterns and IVIg use to treat immune thrombocytopenia.</p> | <p>Kimmitt C, Smiechowski J, Manji F, Goodyear D, Rydz N, Sidhu D, Lee A, Skeith L</p> |
| <p>Abstract Number: PB 1355 Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies</p> | <p>Long vaccine-induced immune thrombotic thrombocytopenia: a case report</p> | <p>Roberge G, Carrier M</p> |
| <p>Abstract Number: PB 1426 Theme: Vascular Biology</p> | <p>Studies of Streptozotocin-Induced Hyperglycemia on the Host Response to Sepsis</p> | <p>Carlin S, Cani E, Sharma N, Dwivedi D, Venegas-Pino D, Werstuck G</p> |
| <p>Abstract Number: PB 1462 Theme: Venous Thromboembolism</p> | <p>The Safety of Anticoagulation in Electroconvulsive Therapy – A Systematic Review</p> | <p>Deng L, Dutta D, Koolian M, Cafaro T</p> |
| <p>Abstract Number: PB 1482 Theme: Venous Thromboembolism</p> | <p>Thrombelastography Identifies Persistent Platelet-mediated Hypercoagulability in Patients with Metastatic Bone Disease Requiring Orthopaedic Surgery</p> | <p>Yamaura L, Skeith L, Monument M, Schneider P</p> |
| <p>Abstract Number: PB 1487 Theme: Venous Thromboembolism</p> | <p>Venous Thromboembolism and Major Bleeding Risk in Hospitalized Obese Patients Receiving Thromboprophylaxis with Enoxaparin</p> | <p>Carrier M, Arcelus J, Stroh C, Khan I, Djoudi Y, Ponomareva E, Ageno W</p> |
| <p>Abstract Number: PB 1528 Theme: Women's Health</p> | <p>Understanding patients' perspectives and barriers to postpartum clinical trial participation: A qualitative substudy of the pilot PARTUM trial</p> | <p>Andrew L, Garven A, Taylor T, Roggensack A, McCarthy C, Dubois S, Duffett L, Rodger M, Skeith L</p> |

Wednesday June 28th, 2023

| Day/ Time/ Location/ Theme | Title | Authors |
|--|---|--|
| Time: 10:45 – 11:00 Location: Rm 710 A Abstract Number: OC 71.3 Theme: Venous Thromboembolism | The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer therapies | Wang T-F, Hill M, Chaudry H, Unachukwu U, Mallick R, Delluc A, Carrier M |
| Time: 11:00 – 11:15 Location: Rm 710 B Abstract Number: OC 72.4 Theme: Venous Thromboembolism | Risk of venous thromboembolism (VTE) in first-degree relatives of patients with VTE compared with general population VTE risk | Robin S, Delluc A, |
| Time: 11:45 – 12:15 Location: Rm 516 Abstract Number: PL 05.1 | ISTH 2023 Congress Highlights - Clinical | Kahn S |